Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer

Wang, XW; Luo, X; Tian, YP; Wu, T; Weng, J; Li, Z; Ye, F; Huang, XF

Ye, F (corresponding author), Xiamen Univ, Dept Med Oncol, Affiliated Hosp 1, Xiamen 361003, Peoples R China.; Ye, F (corresponding author), Xiamen Univ, Xiamen Key Lab Antitumor Drug Transformat Res, Affiliated Hosp 1, Xiamen 361003, Peoples R China.; Li, Z (corresponding author), Xiamen Nuokangde Biol Technol Co Ltd, Xiamen 361006, Peoples R China.; Huang, XF (corresponding author), Michigan State Univ, Inst Quantitat Hlth Sci & Engn, Dept Chem & Biomed Engn, E Lansing, MI 48824 USA.

ACS CHEMICAL BIOLOGY, 2021; 16 (4): 724

Abstract

While Cetuximab can be used to treat KRAS wild-type colon cancer cells by targeting EGFR and inhibiting the activation of downstream signaling pathway......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索